Inhibitor Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2018 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Inhibitor Therapeutics, Inc. annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2018 to Q1 2023.
  • Inhibitor Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2023 was -$411K, a 922% decline year-over-year.
  • Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$411K, a 328% decline from 2022.
  • Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $180K, a 2.27% increase from 2021.
  • Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $176K, a 82.2% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$411K -$461K -922% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q1 2022 $50K -$51K -50.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q1 2021 $101K +$101K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q1 2020 $0 -$1M -100% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q1 2019 $1M -$1.36M -57.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q1 2018 $2.36M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.